FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
OPKO Health, Inc. Stock AnalysisComprehensive stock analysis for OPKO Health, Inc. (OPK) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisOPK
OPK
OPKO Health, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OPK
Home🔹Stocks🔹OPKO Health, Inc.

OPKO Health, Inc.

🇺🇸OPK•NASDAQ

OPKO Health, Inc.

🇺🇸OPK•NASDAQ
Market cap
$1.17B
Sentiment

Your view on OPK

Mkt Cap
$1.17B
Sentiment
Your view
OPK
OPKO Health, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OPK
Company Overview

Overview

What the company does, where it operates, and who runs it.

About OPKO Health, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Phillip Frost
Headquarters
4400 Biscayne Boulevard, Miami, FL, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Phillip Frost
Headquarters
4400 Biscayne Boulevard, Miami, FL, US
Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins.

The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.

In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for OPKO Health, Inc., and the rating behind it. OPK last traded at $1.57; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for OPKO Health, Inc.. Starting points for OPKO Health, Inc.: EPS -$0.10, beta 1.50 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for OPKO Health, Inc.. OPKO Health, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for OPKO Health, Inc.. Trailing twelve-month EPS for OPKO Health, Inc. stands at -$0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for OPKO Health, Inc.. OPKO Health, Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

OPKO Health, Inc. valued side by side against its closest peers. OPKO Health, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold OPKO Health, Inc., and how their positions are changing. At a $1.17B market value, institutional positions materially move OPKO Health, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by OPKO Health, Inc. executives and directors. Shares of OPKO Health, Inc. have traded between $1.11 and $2.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming OPKO Health, Inc.. OPKO Health, Inc. is a $1.17B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming OPKO Health, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for OPKO Health, Inc.. Coverage tracks OPKO Health, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • CTEV — Claritev Corporation
  • DNTH — Dianthus Therapeutics, Inc.
  • LFMD — LifeMD, Inc.
  • NKTR — Nektar Therapeutics
  • OCS — Oculis Holding AG
  • PCRX — Pacira BioSciences, Inc.
  • PSNL — Personalis, Inc.
  • SANA — Sana Biotechnology, Inc.

More Medical - Diagnostics & Research companies

  • WUXIF — WuXi AppTec Co., Ltd.
  • XGN — Exagen Inc.
  • SKHHY — Sonic Healthcare Limited
  • SLDX — Stella Diagnostics Inc.
  • SPDE — Speedus Corp.
  • SZLSF — StageZero Life Sciences Ltd.
  • TDSGF — Telo Genomics Corp.
  • TELO.V — Telo Genomics Corp.
  • THOXF — BioPorto A/S
  • TMO — Thermo Fisher Scientific Inc.
  • TMO.NE — Thermo Fisher Scientific Inc.
  • TOMDF — Todos Medical Ltd.

ETFs holding OPKO Health, Inc.

  • QQQS — Invesco NASDAQ Future Gen 200 ETF (0.53%)
  • ISRA — VanEck Israel ETF (0.42%)
  • XHS — State Street SPDR S&P Health Care Services ETF (0.40%)
  • IHF — iShares US Healthcare Providers ETF (0.10%)
  • SMMV — iShares MSCI USA Small-Cap Min Vol Factor ETF (0.08%)

News

Latest Market News